Form 483

Acrotech Biopharma Inc. Form 483, 2024-11-18

FDA issued a Form 483 to Acrotech Biopharma Inc. on 2024-11-18 with 3 public-safe observations.

483· Form 483 issuedHuman Drugs3 observations

Acrotech Biopharma Inc. · East Windsor, United States · Issued November 18, 2024

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

18 Nov 2024
21 CFR 314.80(b)

Failure to develop written procedures

Cited by Mayar M Mussa

18 Nov 2024
21 CFR 314.80(c)(1)(i)

Late submission of 15-day report

Cited by Mayar M Mussa

18 Nov 2024
21 CFR 314.80(d)

Failure to submit scientific article

Cited by Mayar M Mussa

Inspected site

ABAcrotech Biopharma Inc.East Windsor, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 314.80(b)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 314.80(d)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere